Shuttle Pharmaceuticals Reports Director and Officer Changes
Ticker: SHPH · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance
Related Tickers: SHPH
TL;DR
Shuttle Pharma (SHPH) filed an 8-K for director/officer changes effective 9/12.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 18, 2025, reporting changes effective September 12, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the changes were not elaborated in the provided text.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty and signal potential strategic shifts, requiring closer investor scrutiny.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- September 12, 2025 (date) — Effective date of reported events
- September 18, 2025 (date) — Filing date of the 8-K
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in the excerpt.
Were there any changes to compensatory arrangements for officers?
Yes, the filing states that it covers 'Compensatory Arrangements of Certain Officers,' but the details of these arrangements are not included in the provided text.
What is the effective date of the reported events?
The earliest event reported is dated September 12, 2025.
When was this 8-K form filed with the SEC?
This Form 8-K was filed as of September 18, 2025.
What is the primary business of Shuttle Pharmaceuticals Holdings, Inc.?
Shuttle Pharmaceuticals Holdings, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-18 17:11:44
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-25-014097.txt ( ) — 199KB
- shph-20250912.xsd (EX-101.SCH) — 3KB
- shph-20250912_lab.xml (EX-101.LAB) — 33KB
- shph-20250912_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: September 18, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer 3